DengiAll

The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India’s first-ever Phase 3 clinical trial for the indigenous tetravalent dengue vaccine, DengiAll.

  • Trial Launch Location: PGIMS, Rohtak.
  • Vaccine Strain Origin: Based on TV003/TV005, developed by National Institutes of Health (NIH), USA.
  • Scope of Trial:
    • Conducted across 19 sites in 18 states/UTs.
    • Involves 10,335 healthy adult participants.
  • Panacea Biotec is at the most advanced stage of vaccine development among Indian ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Current Affairs